Company news
Achieve Life Sciences, Inc. (NASDAQ:ACHV) news
Achieve Life Sciences, Inc. news releases on 6ix. Latest, Oct 6, 2026: Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Press releases & updates
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
October 6, 2026
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
October 1, 2026
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
September 30, 2026
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
September 28, 2026
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
August 3, 2026
Achieve Life Sciences Joins Russell 2000® Index
June 29, 2026
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
June 22, 2026
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
June 2, 2026
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
May 19, 2026
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
May 12, 2026
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
May 5, 2026
Achieve Life Sciences : Amendment to Annual Report (Form 10-K/A)
April 30, 2026
Achieve Life Sciences Announces Up to $354 Million Private Placement
April 15, 2026
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
April 15, 2026
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
April 14, 2026
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
March 25, 2026
Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
March 17, 2026
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
March 4, 2026
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
January 30, 2026
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
January 12, 2026
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
December 17, 2025
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
November 6, 2025
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
November 3, 2025
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
October 29, 2025
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
October 20, 2025
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
October 17, 2025
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
October 2, 2025
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
September 22, 2025
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
September 18, 2025
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
September 11, 2025
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
September 3, 2025
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
September 2, 2025
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
August 7, 2025
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2025
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025
July 24, 2025
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
June 30, 2025
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
June 26, 2025
Achieve Life Sciences Announces Proposed Underwritten Public Offering
June 26, 2025
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
June 26, 2025
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
June 26, 2025
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
May 20, 2025
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
May 13, 2025
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
May 6, 2025
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
April 21, 2025
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
March 11, 2025
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
March 7, 2025